Showing results (541-550 of 928) with videos related to

Sort By:
Pageof 93
Der Unfallchirurg|September 23, 2016
[Posttraumatic deformities of the knee joint : Intra-articular osteotomy after malreduction of tibial head fractures]K-H Frosch, M Krause, J Frings, et al.
European Journal of Applied Physiology and Occupational Physiology|January 1, 1989
Ratings of perceived exertion in individuals with varying fitness levels during walking and runningM J Berry, A S Weyrich, R A Robergs, et al.
Archiv Der Pharmazie|April 1, 1996
New potent azomethine prodrugs of the histamine H3-receptor agonist (R)-alpha-methylhistamine containing a heteroarylphenyl partial structureM Krause, A Rouleau, H Stark, et al.
Journal of Science and Medicine in Sport|June 25, 2014
Understanding mismatches in body size, speed and power among adolescent rugby union playersLyndon M Krause, Geraldine A Naughton, Greg Denny, et al.
Biomolecular NMR Assignments|July 30, 2025
<sup>1</sup>H, <sup>13</sup>C and <sup>15</sup>N chemical shift assignment for stem-loop 5a from the 5'UTR of HCoV-229ENina M Krause, Anna Wacker, Christian Richter, et al.
Science Advances|November 22, 2024
Late Archaic large-scale fisheries in the wetlands of the pre-Columbian Maya LowlandsEleanor Harrison-Buck, Samantha M Krause, Marieka Brouwer Burg, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant EnterobacteriaceaeM Thwaites, D Hall, D Shinabarger, et al.
The Journal of Antimicrobial Chemotherapy|February 9, 2010
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemiaSharath S Hegde, Robert Skinner, Stacey R Lewis, et al.
Antimicrobial Agents and Chemotherapy|April 30, 2008
In vitro activity of telavancin against resistant gram-positive bacteriaKevin M Krause, Marika Renelli, Stacey Difuntorum, et al.
The Journal of Antimicrobial Chemotherapy|April 22, 2008
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance InitiativeDeborah C Draghi, Bret M Benton, Kevin M Krause, et al.
Pageof 93